Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG

glucokinase activator

PB-201 is a kind of dual and partial GKA

DRUG

Placebo

Placebo oral tablet

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

PegBio Co., Ltd.

OTHER

NCT03973515 - Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter